46 results on '"Richardson, P. G."'
Search Results
2. Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
3. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
4. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
5. Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
6. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
7. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
8. EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
9. Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.
10. Reply to G. R. Mohyuddin et al and A. Garfall et al.
11. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
12. Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
13. PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
14. A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma.
15. Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.
16. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.
17. Activity of the NEDD8-specific inhibitor MLN 4924 in multiple myeloma and Waldenström's macroglobulinemia, and effect on miRNA expression.
18. Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).
19. Bone marker assessment as a guide to chronic use of aminobisphosphonates in multiple myeloma.
20. PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM).
21. Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma.
22. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study
23. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer
24. Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial
25. Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study
26. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study
27. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)
28. Effects of defibrotide on tumour adhesion and invasion in multiple myeloma, breast cancer and renal cell cancer
29. Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
30. Long-term responses observed with lenalidomide therapy for patients with relapsed or refractory multiple myeloma
31. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
32. Inhibition of fatty acid synthase induces anti-tumor effect in multiple myeloma
33. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)
34. Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial
35. Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB
36. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma
37. Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)
38. Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
39. Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study
40. Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity
41. Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area.
42. International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation.
43. Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma.
44. Imaging Features of Extramedullary, Relapsed, and Refractory Multiple Myeloma involving the Liver Across Treatment With Cyclophosphamide, Lenalidomide, Bortezomib, and Dexamethasone.
45. Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma.
46. Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.